Authors
Rumi Amano, Hirohito Seki, Kazuki Yasuda, Shoko Yao, Ai Tsuchiya, Kaisuke Miyamoto, Yoshiharu Ishizaka, Kaishi Satomi, Yoshika Wada, Shigeru Imoto
Published in
Gan to kagaku ryoho. Cancer & chemotherapy. Volume 53. Issue 9. Pages 587-591.
Abstract
A woman in her 50s was diagnosed with Stage ⅡA triple-negative breast cancer (TNBC) and neoadjuvant chemotherapy with pembrolizumab, carboplatin, and paclitaxel was initiated. On day 125 of treatment, the patient presented to the emergency department with fever and impaired mobility. After a thorough examination, she was diagnosed with fulminant type 1 diabetes mellitus (T1DM) due to an immune-related adverse event (irAE). Prompt initiation of fluid resuscitation and insulin therapy led to symptom resolution. The patient was discharged on day 17 of hospitalization. One month later, adjuvant doxorubicin and cyclophosphamide (AC) therapy was initiated and completed for 4 courses. Subsequently, the patient achieved a clinical complete response (cCR) following neoadjuvant therapy, and subsequently underwent total mastectomy and sentinel lymph node biopsy of the left breast. The final pathological examination revealed a pathological complete response (pCR; ypT0/ypN0). Pembrolizumab was not administered postoperatively. One year after surgery, no evidence of recurrence was observed. Fulminant T1DM is a rare irAE with an incidence of < 0.1%. However, this condition rapidly progresses to diabetic ketoacidosis. When pembrolizumab is administered, early detection through regularly monitoring the patient's symptoms and blood glucose should be required.
PMID:
42750626
Bibliographic data and abstract were imported from PubMed on 17 Sep 2026.
Advertisement
Stats
- Recommendations n/a n/a positive of 0 vote(s)
- Views 16
- Comments 0